Meeting
2023 ASCO Breakthrough
Clinical applications of measurable residual disease monitoring by multi-parametric flow cytometry and next-generation sequencing in B-cell precursor acute lymphoblastic leukemia.
Authors
Gun-Dong Lee
Department of Laboratory Medicine, Seoul St. Mary's Hospital, Seoul, South Korea
Gun-Dong Lee , Ari Ahn , Jong-Mi Lee , Myungshin Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Real-World Evidence/Real-World Data
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 121)
DOI
10.1200/GO.2023.9.Supplement_1.121
Abstract #
121
Poster Bd #
F4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Comparison of next-generation sequencing and flow cytometry in detecting minimal residual disease in adult acute lymphoid leukemia: Evaluating clinical outcomes in a single-center study.
First Author: Vinay Nittur
Poster
2013 ASCO Annual Meeting
A comparison between next-generation sequencing and ASO-qPCR for minimal residual disease detection in multiple myeloma.
First Author: Hiroyuki Takamatsu
Poster
2023 ASCO Annual Meeting
Treatment outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: A comparison between pediatric-inspired regimens and HyperCVAD at a Hispanic-serving cancer center.
First Author: Shawn Patrick Griffin
Poster
2022 ASCO Annual Meeting
Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).
First Author: Walid Macaron